Wells Fargo
TGTX icon

Wells Fargo’s TG Therapeutics TGTX Stock Holding History

Wells Fargo’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,000
Closed -$36K – 7392
2025
Q2 		$36K Buy
+1,000
New +$37.2K ﹤0.01% 5617
2022
Q2 		– Sell
-10,900
Closed -$104K – 7481
2022
Q1 		$104K Buy
+10,900
New +$126K ﹤0.01% 5314

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Wells Fargo's TGTX Position: Q2 2026 in Review

Wells Fargo increased its TG Therapeutics (TGTX) stake by 13% in Q2 2026, buying an estimated $1.77M and bringing the position to 375,894 shares worth $20.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1610.

Wells Fargo first reported a position in TGTX in Q2 2013 and has held it in 53 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Wells Fargo held 375,894 shares of TG Therapeutics worth $20.7M as of Q2 2026.
  • Wells Fargo bought 43,174 TG Therapeutics shares in Q2 2026, an estimated $1.77M.
  • TG Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #1610 holding.
  • Wells Fargo first reported a position in TG Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.